trending Market Intelligence /marketintelligence/en/news-insights/trending/w3yrlyedo_sqxhy-rs4ouq2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Pfizer's drug for rare heart disease meets goal in phase 3 trial

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Pfizer's drug for rare heart disease meets goal in phase 3 trial

Pfizer Inc. said Tafamidis, an experimental treatment for a rare heart condition, met the main goal of a phase 3 trial.

The medicine for transthyretin cardiomyopathy, a condition that causes heart failure, reduced premature deaths and the frequency of heart-related hospitalizations compared to placebo after 30 months of treatment, the New York-based pharmaceutical company said.

Tafamidis was well tolerated by the patients with no new safety issues, Pfizer said.

Transthyretin cardiomyopathy occurs due to the collection and deposition of the transthyretin protein in the heart. These proteins then infiltrate the heart muscle, eventually causing heart failure, or the inability of the organ to adequately pump blood.

The average life expectancy for people with transthyretin cardiomyopathy is three to five years from diagnosis and only about 1% of people with the disease are diagnosed, according to Pfizer.

The company said there are no medicines specifically approved for treating transthyretin cardiomyopathy. Tafamidis was granted orphan drug designation for the rare disease in both the EU and U.S. in 2011, Pfizer said.

In June 2017, the U.S. Food and Drug Administration granted fast-track designation to the experimental drug for the same use.

Pfizer said that in March, Japan's Ministry of Health, Labour and Welfare granted tafamidis a Sakigake designation for the disease. A Sakigake designation can result in faster approval of drugs.